{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05345444\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RTIRE","nct_id":"NCT05345444","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rtire-nct05345444. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"RTIRE","arms":[{"description":null,"label":"Irreversible Electroporation and Radiotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":48,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"IRE & MRgRT","type":"DEVICE"}],"last_update":"2026-07-29","lead_sponsor":"Weill Medical College of Cornell University","official_title":"Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2026-04-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Feasibility as measured by percentage of subjects assessed at 12 weeks post-IRE","timeFrame":"12 weeks"},{"measure":"Feasibility as measured by percentage of subjects assessed at 6 weeks post-MRgRT within 1 year","timeFrame":"6 weeks"},{"measure":"Proportion of patients who remain cancer-free","timeFrame":"12 months"}],"references":[{"citation":"Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008 Feb;15(1):3866-71.","pmid":"18304396","type":"BACKGROUND"},{"citation":"NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer (Version 2.2017). (2017)","pmid":null,"type":"BACKGROUND"},{"citation":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.","pmid":"30735235","type":"BACKGROUND"},{"citation":"Mahase SS, D'Angelo D, Kang J, Hu JC, Barbieri CE, Nagar H. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. JAMA Netw Open. 2020 Feb 5;3(2):e1920471. doi: 10.1001/jamanetworkopen.2019.20471.","pmid":"32022878","type":"BACKGROUND"},{"citation":"Kang JK, Cho CK, Choi CW, Yoo S, Kim MS, Yang K, Yoo H, Kim JH, Seo YS, Lee DH, Jo M. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori. 2011 Jan-Feb;97(1):43-8. doi: 10.1177/030089161109700109.","pmid":"21528663","type":"BACKGROUND"},{"citation":"Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Loblaw A. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol. 2020 May;146:90-96. doi: 10.1016/j.radonc.2020.02.009. Epub 2020 Mar 5.","pmid":"32146259","type":"BACKGROUND"},{"citation":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bjornlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellen E, Franzen L, Nilsson P. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.","pmid":"31227373","type":"BACKGROUND"},{"citation":"Vogelius IR, Bentzen SM. Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865. doi: 10.1016/j.ijrobp.2017.12.011. Epub 2017 Dec 15.","pmid":"29485063","type":"BACKGROUND"},{"citation":"Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, van Vulpen M, Draulans C, van den Bergh L, Isebaert S, van der Heide UA. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):787-796. doi: 10.1200/JCO.20.02873. Epub 2021 Jan 20.","pmid":"33471548","type":"BACKGROUND"},{"citation":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, Groen VH, Monninkhof EM, Smeenk RJ, Kunze-Busch M, De Roover R, Depuydt T, Isebaert S, Kerkmeijer LGW. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020 Jun;147:92-98. doi: 10.1016/j.radonc.2020.03.015. Epub 2020 Apr 1.","pmid":"32247206","type":"BACKGROUND"},{"citation":"Van Andel G, Visser AP, Hulshof MC, Horenblas S, Kurth KH. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU Int. 2003 Aug;92(3):217-22. doi: 10.1046/j.1464-410x.2003.04321.x.","pmid":"12887470","type":"BACKGROUND"},{"citation":"Diven M, Ballman K, Marciscano A, Barbieri C, Piscopo J, Wang S, Nagar H, McClure T. Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE). BMC Urol. 2024 Jul 25;24(1):151. doi: 10.1186/s12894-024-01506-8.","pmid":"39054460","type":"DERIVED"}],"start_date":{"date":"2022-05-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)","url":"https://clinicaltrials.gov/study/NCT05345444"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rtire-nct05345444"}